80 related articles for article (PubMed ID: 34265433)
1. Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study.
Ai X; Wang Q; Cheng Y; Liu X; Cao L; Chen J; Dong X; Zhou J; Fan Y; Huang C; Cui J; Wang Y; Chen G; Ding C; Gao B; Li X; Wang Z; Zhang H; Ding L; Wang Y; Yuan X; Cheng H; Wang T; Lu S
J Thorac Oncol; 2021 Nov; 16(11):1959-1963. PubMed ID: 34265433
[TBL] [Abstract][Full Text] [Related]
2. Repotrectinib in
Drilon A; Camidge DR; Lin JJ; Kim SW; Solomon BJ; Dziadziuszko R; Besse B; Goto K; de Langen AJ; Wolf J; Lee KH; Popat S; Springfeld C; Nagasaka M; Felip E; Yang N; Velcheti V; Lu S; Kao S; Dooms C; Krebs MG; Yao W; Beg MS; Hu X; Moro-Sibilot D; Cheema P; Stopatschinskaja S; Mehta M; Trone D; Graber A; Sims G; Yuan Y; Cho BC;
N Engl J Med; 2024 Jan; 390(2):118-131. PubMed ID: 38197815
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of ensartinib-treated
Yuan X; Wang Y; Yang M; Wu P; Chen H; Yun Y; Shen Z; Ji D; Ma Y; Ding L
Lung Cancer Manag; 2023 Dec; 12(4):LMT61. PubMed ID: 38239813
[TBL] [Abstract][Full Text] [Related]
4. Ensartinib rapidly relieves symptoms in ALK positive patients with brain metastases.
Xu H; Chen T; Zheng Y; Fang W
Asian J Surg; 2024 May; ():. PubMed ID: 38749835
[No Abstract] [Full Text] [Related]
5. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
He J; Su C; Liang W; Xu S; Wu L; Fu X; Zhang X; Ge D; Chen Q; Mao W; Xu L; Chen C; Hu B; Shao G; Hu J; Zhao J; Liu X; Liu Z; Wang Z; Xiao Z; Gong T; Lin W; Li X; Ye F; Liu Y; Ma H; Huang Y; Zhou J; Wang Z; Fu J; Ding L; Mao L; Zhou C
Lancet Respir Med; 2021 Sep; 9(9):1021-1029. PubMed ID: 34280355
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Zhou Q; Xu CR; Cheng Y; Liu YP; Chen GY; Cui JW; Yang N; Song Y; Li XL; Lu S; Zhou JY; Ma ZY; Yu SY; Huang C; Shu YQ; Wang Z; Yang JJ; Tu HY; Zhong WZ; Wu YL
Cancer Cell; 2021 Sep; 39(9):1279-1291.e3. PubMed ID: 34388377
[TBL] [Abstract][Full Text] [Related]
7. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.
Jassem J; de Marinis F; Giaccone G; Vergnenegre A; Barrios CH; Morise M; Felip E; Oprean C; Kim YC; Andric Z; Mocci S; Enquist I; Komatsubara K; McCleland M; Kuriki H; Villalobos M; Phan S; Spigel DR; Herbst RS
J Thorac Oncol; 2021 Nov; 16(11):1872-1882. PubMed ID: 34265434
[TBL] [Abstract][Full Text] [Related]
8. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
[TBL] [Abstract][Full Text] [Related]
9. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
Yang Y; Sun J; Wang Z; Fang J; Yu Q; Han B; Cang S; Chen G; Mei X; Yang Z; Ma R; Bi M; Ren X; Zhou J; Li B; Song Y; Feng J; Li J; He Z; Zhou R; Li W; Lu Y; Zhou H; Wang S; Sun L; Puig O; Mancao C; Peng B; Fang W; Xu W; Zhang L
J Thorac Oncol; 2021 Dec; 16(12):2109-2120. PubMed ID: 34358724
[TBL] [Abstract][Full Text] [Related]
10. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
Socinski MA; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kong S; Lee A; Coleman S; Zou W; McCleland M; Shankar G; Reck M
J Thorac Oncol; 2021 Nov; 16(11):1909-1924. PubMed ID: 34311108
[TBL] [Abstract][Full Text] [Related]
11. Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor.
Zhu VW; Ou SI
J Thorac Oncol; 2021 Nov; 16(11):1778-1781. PubMed ID: 34715999
[No Abstract] [Full Text] [Related]
12. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
[TBL] [Abstract][Full Text] [Related]
13. A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study.
Zhou Q; Wu L; Hu P; An T; Zhou J; Zhang L; Liu XQ; Luo F; Zheng X; Cheng Y; Yang N; Li J; Feng J; Han B; Song Y; Wang K; Zhang L; Fang J; Zhao H; Shu Y; Lin XY; Chen Z; Gan B; Xu WH; Tang W; Zhang X; Yang JJ; Xu X; Wu YL
Clin Cancer Res; 2022 Mar; 28(6):1127-1135. PubMed ID: 34740925
[TBL] [Abstract][Full Text] [Related]
14. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With
Tada H; Mitsudomi T; Misumi T; Sugio K; Tsuboi M; Okamoto I; Iwamoto Y; Sakakura N; Sugawara S; Atagi S; Takahashi T; Hayashi H; Okada M; Inokawa H; Yoshioka H; Takahashi K; Higashiyama M; Yoshino I; Nakagawa K;
J Clin Oncol; 2022 Jan; 40(3):231-241. PubMed ID: 34726958
[TBL] [Abstract][Full Text] [Related]
16. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
Dziadziuszko R; Mok T; Peters S; Han JY; Alatorre-Alexander J; Leighl N; Sriuranpong V; Pérol M; de Castro Junior G; Nadal E; de Marinis F; Frontera OA; Tan DSW; Lee DH; Kim HR; Yan M; Riehl T; Schleifman E; Paul SM; Mocci S; Patel R; Assaf ZJ; Shames DS; Mathisen MS; Gadgeel SM
J Thorac Oncol; 2021 Dec; 16(12):2040-2050. PubMed ID: 34311110
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.
Koch AL; Vellanki PJ; Drezner N; Li X; Mishra-Kalyani PS; Shen YL; Xia H; Li Y; Liu J; Zirkelbach JF; Palazov E; Gamarian A; Choo Q; Girčys A; Rohr UP; Fesenko N; Spillman D; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2021 Dec; 27(24):6638-6643. PubMed ID: 34301748
[TBL] [Abstract][Full Text] [Related]
18. Lung cancer.
Thai AA; Solomon BJ; Sequist LV; Gainor JF; Heist RS
Lancet; 2021 Aug; 398(10299):535-554. PubMed ID: 34273294
[TBL] [Abstract][Full Text] [Related]
19. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
[TBL] [Abstract][Full Text] [Related]
20. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Acta Pharm Sin B; 2021 Oct; 11(10):2983-2994. PubMed ID: 34729299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]